A Dual-Targeting Biomimetic Nanozyme Triggering Hypoxia Relief and Macrophage Reprogramming for Synergistic HCC Immunochemotherapy
The treatment effectiveness for hepatocellular carcinoma (HCC) is often hindered by an immunosuppressive tumor microenvironment (TME), marked by persistent hypoxia and a high presence of tumor-promoting M2-like tumor-associated macrophages (TAMs). To overcome these barriers, we engineered a dual-targeting biomimetic...